Bone loss from glucocorticoids
- Follow-up and treatment
Steroid tablets are the medicine that most often breaks bones, and the damage starts within months. Protecting bone should start with the prescription.
See it in 3D: L1 vertebra · L2 vertebra · Femur
What it is
Glucocorticoid-induced osteoporosis is the commonest secondary osteoporosis. Bone loss is fastest in the first months of treatment and hits trabecular bone first, so vertebral fractures come first. Risk rises with the daily dose and the length of treatment, appears even at low daily doses, and falls partly after the drug is stopped. Glucocorticoids mainly switch off bone formation (osteoblasts and osteocytes die early and Wnt signalling is blocked), while early on they also speed resorption; they reduce calcium absorption in the gut, increase calcium loss in the urine, lower sex hormones and weaken muscle, so falls increase. Fractures happen at a better bone density than in postmenopausal osteoporosis, so DXA and standard FRAX underestimate the risk. The same happens in endogenous Cushing syndrome.
What to know
- Assess everyone expected to take oral glucocorticoids for 3 months or more, as early as possible: fracture history, falls, height, FRAX and, from about age 40, DXA.
- Standard FRAX underestimates risk at high daily doses; guidelines adjust the result upwards according to the dose taken.
- Use the lowest effective glucocorticoid for the shortest time; prefer steroid-sparing drugs and local routes where possible.
- For everyone: enough calcium and vitamin D, exercise, fall prevention, no smoking, little alcohol.
- Oral bisphosphonates are usually first line; intravenous zoledronic acid, denosumab or a PTH analogue are alternatives, and a PTH analogue fits best when risk is very high because it restores formation.
- Teriparatide reduced vertebral fractures more than alendronic acid in glucocorticoid-treated patients in a head-to-head trial.
- In women who may become pregnant, bisphosphonates are used with caution because they stay in bone for years.
- Inhaled glucocorticoids affect bone much less, though high long-term use adds some risk.
- Stopping glucocorticoids lowers fracture risk partly; when they stop, reassess the need for bone treatment.
Step by step
- When a long glucocorticoid course starts, assess fracture risk within the first months; do not wait for a fracture.
- Optimise calcium and vitamin D intake; check 25-OH vitamin D, calcium and creatinine.
- Grade risk with dose-adjusted FRAX, DXA and previous fractures.
- Moderate or high risk: start an oral bisphosphonate, or an alternative if tablets are not suitable.
- Very high risk (previous fracture, very low T-score, high daily doses): consider a PTH analogue.
- Reassess every 1–2 years while glucocorticoids continue, and again when they stop.
Glucocorticoid-induced versus postmenopausal osteoporosis
| Feature | Glucocorticoid-induced | Postmenopausal |
|---|---|---|
| Main defect | Low bone formation | High bone resorption |
| Speed of loss | Fastest in the first months | Fastest in the first years after menopause |
| Typical first fracture | Vertebrae (trabecular bone) | Vertebrae and wrist, then hip |
| Density at fracture | Often only osteopenic | Usually lower |
| Reversibility | Risk falls partly after stopping | Persistent |
| Best fit at very high risk | PTH analogue (restores formation) | Anabolic, then antiresorptive |
In the clinic
- Bone protection is often forgotten in rheumatology, respiratory, skin and transplant patients on long courses: build it into the first prescription.
- Back pain in a patient on glucocorticoids is a vertebral fracture until proven otherwise: image the spine.
- Myopathy and falls add to bone fragility: check proximal strength and fall risk.
- In children on long courses, growth and bone health both need monitoring.
Next step / Initial management
- At the start: calcium, creatinine and 25-OH vitamin D; DXA from about age 40 or with a previous fracture; spine X-ray if there is back pain or height loss.
- Supplement calcium and vitamin D when intake is low, and start bone treatment according to risk.
- Repeat DXA every 1–2 years while treatment continues.
- Think of endogenous Cushing syndrome when fragile bones and Cushing features appear without glucocorticoid use.
- Refer to endocrinology fractures despite treatment, very high risk needing an anabolic, children, premenopausal women, or suspected endogenous Cushing syndrome.
Common traps
- Low-dose glucocorticoids are safe for bone: fracture risk rises even at low daily doses, and it rises within months.
- A T-score above −2.5 means no bone treatment on glucocorticoids: these patients fracture at better densities, so risk is judged by dose, fractures and an upward-adjusted FRAX.
- Bone protection can wait until the course is over: loss is fastest in the first three to six months, so protection starts with the prescription.
- Antiresorptives target the main problem: the main defect is suppressed formation; antiresorptives still help, but a PTH analogue fits best when risk is very high.
- Inhaled steroids carry the same bone risk as tablets: their effect on bone is much smaller, though high long-term use adds some.
Test yourself
Think of the answer, then tap the question to see it.
A 58-year-old man has taken prednisolone for polymyalgia rheumatica for 5 months and now has sudden back pain. What is likely, and what was missed?
A vertebral fracture from glucocorticoid-induced osteoporosis. Fracture risk assessment and bone protection should have started with the prescription.
Why do patients on glucocorticoids fracture at better bone densities than postmenopausal women?
Glucocorticoids damage bone quality (osteocyte death, poor microarchitecture) and cause falls through myopathy, which density does not capture.
A 45-year-old woman starting long-term glucocorticoids for lupus has a T-score of −1.8 and a previous vertebral fracture. What is the principle of treatment?
She is at high or very high risk despite osteopenia: calcium and vitamin D plus bone treatment, considering a PTH analogue; bisphosphonates with caution if pregnancy is possible.
What is the main cellular effect of glucocorticoids on bone?
Suppressed bone formation: osteoblasts and osteocytes die early and Wnt signalling falls; resorption rises only in the early phase.
Elsewhere in DurgiPedia
Connections
See it in 3D3
The structures of Durgical's 3D anatomy where it is found.
Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.
Sources: Secondary Osteoporosis (StatPearls (NCBI Bookshelf), 2023); Osteoporosis in Females (StatPearls (NCBI Bookshelf), 2025); Osteoporosis in Males (StatPearls (NCBI Bookshelf), 2025); Teriparatide (StatPearls (NCBI Bookshelf), 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
